Portola Pharmaceuticals has reported financial results for the quarter ended March 31, 2017.
For the first quarter of 2017, Portola reported a net loss of $41.7 million, compared with a net loss of $65.0 million for the same period in 2016.
“During the first quarter of 2017 we continued to focus on regulatory activities for betrixaban and AndexXaTM. Our goal is to gain approval for both products this year in the United States and in 2018 in the European Union,” said Bill Lis, chief executive officer of Portola. “Both are highly anticipated by the medical community because they are potentially life-saving medicines in indications where currently there are no approved therapies.”